Can High Convection Volumes be Achieved in Each Patient During Online Post-dilution Hemodiafiltration?
Launched by AMSTERDAM UMC, LOCATION VUMC · Jun 10, 2013
Trial Information
Current as of May 20, 2025
Completed
Keywords
ClinConnect Summary
Hemodialysis (HD) is the most common used renal replacement therapy worldwide. The main objective is the removal of excess fluid and toxic solutes from the patient. Despite the relative efficiency of modern dialyzers, HD remains inferior to normal kidney function, in part because of the inadequate clearance of so-called 'middle molecules'. In other words, 'uremic toxins' accumulate in chronic HD patients.
The role of middle molecular weight uremic toxins in the pathogenesis of many co-morbid conditions associated with end-stage renal disease is increasingly recognized. Hence, the hypothesi...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients treated with HD or HDF since \>6 weeks, 3 times a week;
- • Patients able to understand the study procedures;
- • Patients willing to provide written informed consent.
- Exclusion Criteria:
- • Current age \< 18 years;
- • Severe incompliance to dialysis procedure and accompanying prescriptions (frequency and duration of dialysis treatment and fluid restriction);
- • Life expectancy \< 3 months due to non-renal disease.
About Amsterdam Umc, Location Vumc
Amsterdam UMC, located at VU Medical Center (VUmc), is a leading academic medical center in the Netherlands dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on translating scientific discoveries into practical applications, Amsterdam UMC collaborates closely with researchers, healthcare professionals, and industry partners to enhance patient outcomes. The institution is committed to rigorous ethical standards and regulatory compliance, ensuring the integrity and reliability of its clinical research initiatives across various medical disciplines.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Utrecht, , Netherlands
Amsterdam, , Netherlands
Eindhoven, , Netherlands
Groningen, , Netherlands
Rotterdam, , Netherlands
Amsterdam, , Netherlands
Amsterdam, , Netherlands
Patients applied
Trial Officials
Peter J Blankestijn, MD PhD
Study Director
UMC Utrecht
Michiel L Bots, MD PhD
Study Director
Julius Center for Health Sciences and Primary Care, UMC Utrecht
Marinus A van den Dorpel, MD PhD
Study Director
Maasstad Hospital, Rotterdam
Menso J Nubé, MD PhD
Study Chair
Amsterdam UMC, location VUmc
Piet M ter Wee, MD PhD
Study Director
Amsterdam UMC, location VUmc
Muriel PC Grooteman, MD PhD
Principal Investigator
Amsterdam UMC, location VUmc
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials